Why the study?
Does Factor V Leiden increase perioperative hemorrhagic and thrombotic risk in surgical patients?
Does Factor V Leiden increase perioperative hemorrhagic and thrombotic risk in surgical patients?
This review highlights the need for comprehensive investigation into the perioperative hemorrhagic and thrombotic risks associated with Factor V Leiden in surgical patients.
Perioperative management of Factor V Leiden patients should not change; leaves open the magnitude of hemorrhagic and thrombotic risks pending targeted studies.
Factor V Leiden (FVL) is the most common known inherited cause of thrombophilia; it is present in approximately 5% of the Caucasian population. Although the risk of venous thrombosis associated with this polymorphism in various medical settings is well described, its effect on perioperative risk is only beginning to be explored. Specifically, there are few studies addressing the potential risks of FVL in the surgical population, in which both hemorrhagic and thrombotic complications convey substantial clinical and economic significance. There are speculations and unproven hypotheses regarding FVL in this population, and these therefore highlight the need to comprehensively address this issue. This review will describe the physiology of the FVL mutation, briefly clarify its risk in the nonsurgical setting, and assess current data regarding FVL in noncardiac and cardiac surgery. Finally, a summary of current clinical evidence and a plan for more detailed investigation of this potentially significant risk factor will be proposed.
No takes yet. Share an insight, caveat, or question.
Brian S. Donahue (2004) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: